Observational study of Pertuzumab in combination with Trastuzumab and Docetaxel in patients with metastatic HER2-positive breast cancer that have the history of Trastuzumab treatment
Not Applicable
Recruiting
- Conditions
- metastatic breast cancer
- Registration Number
- JPRN-UMIN000012444
- Lead Sponsor
- Osaka City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Male patients 2. Patients with allergy to the medicines in this protocol treatment. 3. Active infection or fever suspicious of infection. 4. Pregnant women, nursing mothers, women with possibility of pregnancy or women with no intention to contraception. 5. Other patients who were considered by the primary care physician to be inappropriate as subjects of this trial.
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method